NervGen Pharma Corp. (NGENF)
- Previous Close
1.5000 - Open
1.5025 - Bid --
- Ask --
- Day's Range
1.5025 - 1.5800 - 52 Week Range
1.1000 - 2.9900 - Volume
50,284 - Avg. Volume
76,498 - Market Cap (intraday)
108.388M - Beta (5Y Monthly) 1.46
- PE Ratio (TTM)
-- - EPS (TTM)
-0.2800 - Earnings Date May 13, 2024 - May 17, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
NervGen Pharma Corp., together with its subsidiaries, engages in the discovery, development, and commercialization of pharmaceutical treatments for medical conditions related to nervous system damage. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), multiple sclerosis, and Alzheimer's disease. It has a licensing agreement with Case Western Reserve University to research, develop, and commercialize a patented technology with therapeutic potential for spinal cord injury and other conditions associated with nerve damage. The company was incorporated in 2017 and is based in Vancouver, Canada.
www.nervgen.comRecent News: NGENF
Performance Overview: NGENF
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NGENF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NGENF
Valuation Measures
Market Cap
108.02M
Enterprise Value
99.63M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
27.02
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-4.48
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-59.88%
Return on Equity (ttm)
-390.89%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-22.38M
Diluted EPS (ttm)
-0.2800
Balance Sheet and Cash Flow
Total Cash (mrq)
11.66M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-303.87k
Company Insights: NGENF
NGENF does not have Company Insights